查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1858789

苯达莫司汀：全球市场份额和排名、总销售额和需求预测（2025-2031 年）

Bendamustine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球苯达莫司汀市场规模预计为 4.16 亿美元，预计到 2031 年将萎缩至 2.9 亿美元，2025 年至 2031 年的复合年增长率为 -4.9%。

本报告对近期苯达莫司汀的关税调整和国际策略反制措施进行了全面评估，评估内容包括跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组。

苯达莫司汀是一种化疗药物，用于治疗慢性淋巴性白血病（CLL）、多发性骨髓瘤和非何杰金氏淋巴瘤。它是透过静脉注射给药。 2024年，全球苯达莫司汀产量达到约145万单位，全球平均市场价格约为每单位287美元。

鑑于全球骨髓恶性肿瘤负担日益加重以及人口老化，苯达莫司汀的市场前景极具吸引力。慢性淋巴性白血病(CLL)、非何杰金氏淋巴瘤(NHL) 和其他血液系统癌症发生率的不断上升，推动了对有效且耐受性良好的化疗药物的需求——而这正是苯达莫司汀的优势所在。许多国家的公共卫生和政府机构正在更新和扩展淋巴瘤和白血病治疗指南，以促进含苯达莫司汀治疗方法的采用和标准化。同时，联合治疗（化疗合併标靶治疗或免疫疗法）的趋势也在加速发展。苯达莫司汀的作用机制使其能够与这些新型治疗方法合併使用，从而拓展了新的适应症和治疗方法。此外，非专利处方药的出现和生命週期管理策略正在降低成本并提高药物可近性，尤其是在医疗基础设施正在发展的新兴市场（亚太地区、拉丁美洲和东南亚）。

儘管有这些有利因素，苯达莫司汀仍面临许多挑战。首先，新型标靶治疗和免疫疗法，例如CAR-T细胞疗法、单株抗体和小分子抑制剂，在治疗指南和临床实践中日益占据核心地位，这可能会在某些适应症中侵蚀苯达莫司汀的市场份额。其次，其副作用，包括骨髓抑制和感染风险，限制了其在体弱患者和合併其他疾病患者的应用。第三，不同市场的报销、定价政策和法规环境差异显着，严格的定价法规和有限的保险覆盖范围限制了其应用和盈利。第四，专利到期后非专利处方药的竞争可能会降低利润率。最后，在整个生产和供应链中保持品质、纯度和合规性的一致性会带来成本和营运风险。

下游临床需求正转向以精准治疗、联合治疗和便利性为重点的治疗模式。分子生物标记、基因定序和微量残存疾病（MRD）监测等诊断技术的进步，使得早期疗育和个体化治疗成为可能，而苯达莫司汀越来越多地被考虑与免疫疗法和标靶治疗联合应用于这些治疗方法中。患者和医疗系统越来越重视疗效与毒性、生活品质、给药便利性、优化的治疗方案以及成本效益高的副作用管理之间的平衡。新兴市场对经济实惠的学名药和生物相似药的需求强劲，而已开发市场则以新型联合治疗和指南推荐的治疗方案为驱动力。门诊、诊所和居家照护环境的重要性日益凸显，对苯达莫司汀的製剂、给药方法和支持系统提出了更高的要求。

作为合成小分子药物，苯达莫司汀依赖上游工程原料，包括烷化剂中间体、嘌呤类似物中间体、有机化学试剂、高纯度溶剂以及纯化和结晶过程中使用的中间体。甲醇烷基化部分可来自氯代有机化合物、环烷基或氮丙啶/环状结构前驱物。嘌呤类似物部分需要核苷或核碱基前驱物、催化剂、立体化学控制以及极低的杂质含量。高纯度溶剂、金属催化剂或还原剂/氧化剂必不可少，并且需要严格控制残留金属和副产物。供应稳定性受化学中间体或精细化学品生产商的产能、环境法规（特别是关于有机溶剂排放和废弃物处理的法规）、贸易和进出口政策以及特定合成路线的专利保护或独占权的影响。合成、纯化、结晶和中间体处理过程中的品管对于最终药物的稳定性、安全性和监管核准至关重要。该产品的毛利率约为 80%。

本报告旨在按地区/国家、类型和应用程式对全球苯达莫司汀市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

苯达莫司汀市场规模、估算和预测以销售（千）和收入（百万美元）为单位呈现，基准年为2024年，并包含2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法，帮助读者制定苯达莫司汀的业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Teva
  • Eisai
  • Eagle Pharmaceuticals
  • MundiPharma
  • Viatris
  • Apotex
  • Emcure
  • Miracalus Pharma
  • Fresenius
  • Zhengda Tianqing
  • Slayback Pharma
  • SYMBIO SEIYAKU
  • Hikma Pharmaceuticals
  • Natco Pharma
  • Medac GmbH

按类型分類的细分市场

  • 25毫克注射液
  • 100毫克注射液
  • 其他的

应用领域

  • 慢性淋巴性白血病
  • 多发性骨髓瘤
  • 非何杰金氏淋巴瘤

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Bendamustine was estimated to be worth US$ 416 million in 2024 and is forecast to a readjusted size of US$ 290 million by 2031 with a CAGR of -4.9% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Bendamustine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.In 2024, global Bendamustine production reached approximately 1.45 m units, with an average global market price of around US$ 287 perunit.

In the face of a rising global burden of hematologic malignancies and the aging population, the opportunity for bendamustine is highly compelling. Incidence increases in chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and other blood cancers create rising demand for chemotherapy agents that combine efficacy with tolerability-exactly where bendamustine shines. Public health bodies and governmental agencies in many countries have updated or expanded treatment guidelines for lymphomas and leukemia, which boosts adoption and standardization of treatments incorporating bendamustine. In parallel, the movement toward combination regimens (chemotherapy plus targeted or immunotherapy) is accelerating; bendamustine's mechanism allows it to pair with these newer modalities, opening up new indication and regimen expansion. Further, the arrival of generics and lifecycle management strategies reduces cost and increases access, especially in emerging markets (Asia-Pacific, Latin America, Southeast Asia) with improving healthcare infrastructure.

Despite strong tailwinds, bendamustine faces significant challenges. First, novel targeted therapies and immunotherapies-such as CAR-T cell therapy, monoclonal antibodies, and small molecule inhibitors-are increasingly taking center stage in treatment guidelines and clinical practice, which can erode bendamustine's share in some indications. Second, adverse effect profiles-bone-marrow suppression, infection risk, etc.-limit its use in frail patients or those with comorbidities. Third, reimbursement, pricing policies and regulatory environments vary widely; in markets with strict price regulation or limited insurance coverage, uptake and profitability are constrained. Fourth, competition from generics post-patent expiry can drive down margins. Finally, maintaining consistent quality, purity and regulatory compliance across manufacturing and supply chain presents both cost and operational risks.

On the downstream side, clinical demand is shifting toward more precise, combination, and convenience-oriented treatment paradigms. Advances in diagnostic technologies-molecular biomarkers, gene sequencing, minimal residual disease (MRD) monitoring-enable earlier intervention and more tailored therapy; bendamustine, when combined with immunotherapy or targeted agents, is increasingly considered in such regimens. Patients and health systems are placing growing importance on the balance between efficacy and toxicity, quality of life, administration convenience, treatment schedule improvements, and the cost of managing side effects. Markets in emerging economies display strong demand for cost-effective, generic or biosimilar versions; in developed markets, newer combinations or recommended regimens (per guidelines) lead the adoption. Outpatient, clinic-based, or home care settings are also increasingly relevant, imposing higher demands on formulation, delivery, and support of bendamustine products.

Bendamustine, as a synthetic small molecule drug, depends upstream on raw materials including alkylating-agent intermediates, purine analog intermediate building blocks, organic chemical reagents, high-purity solvents, and intermediates used in purification and crystallization steps. The alkylating portion may derive from chloro-organic compounds, cyclic alkyl or aziridine / cyclic moiety precursors; the purine analog side requires nucleoside or nucleobase precursors, catalysts, stereo-chemistry control, and minimal impurities. High-purity solvents, metal catalysts or reducing/oxidizing agents are essential, with tight control over residual metals and by-products. Supply stability is influenced by capacity at chemical intermediates or fine chemicals manufacturers, environmental regulation (especially around organic solvent emissions and waste handling), trade and import/export policies, and patent protections or exclusivity in certain synthetic routes. Quality control in the synthesis, purification, crystallization, and intermediate handling steps is critical for final drug stability, safety, and regulatory approval.The gross profit margin of this product is around 80%.

This report aims to provide a comprehensive presentation of the global market for Bendamustine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Bendamustine by region & country, by Type, and by Application.

The Bendamustine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bendamustine.

Market Segmentation

By Company

  • Teva
  • Eisai
  • Eagle Pharmaceuticals
  • MundiPharma
  • Viatris
  • Apotex
  • Emcure
  • Miracalus Pharma
  • Fresenius
  • Zhengda Tianqing
  • Slayback Pharma
  • SYMBIO SEIYAKU
  • Hikma Pharmaceuticals
  • Natco Pharma
  • Medac GmbH

Segment by Type

  • 25mg Injection
  • 100mg Injection
  • Others

Segment by Application

  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Bendamustine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Bendamustine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Bendamustine in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Bendamustine Product Introduction
  • 1.2 Global Bendamustine Market Size Forecast
    • 1.2.1 Global Bendamustine Sales Value (2020-2031)
    • 1.2.2 Global Bendamustine Sales Volume (2020-2031)
    • 1.2.3 Global Bendamustine Sales Price (2020-2031)
  • 1.3 Bendamustine Market Trends & Drivers
    • 1.3.1 Bendamustine Industry Trends
    • 1.3.2 Bendamustine Market Drivers & Opportunity
    • 1.3.3 Bendamustine Market Challenges
    • 1.3.4 Bendamustine Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Bendamustine Players Revenue Ranking (2024)
  • 2.2 Global Bendamustine Revenue by Company (2020-2025)
  • 2.3 Global Bendamustine Players Sales Volume Ranking (2024)
  • 2.4 Global Bendamustine Sales Volume by Company Players (2020-2025)
  • 2.5 Global Bendamustine Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Bendamustine Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Bendamustine Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Bendamustine
  • 2.9 Bendamustine Market Competitive Analysis
    • 2.9.1 Bendamustine Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Bendamustine Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bendamustine as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 25mg Injection
    • 3.1.2 100mg Injection
    • 3.1.3 Others
  • 3.2 Global Bendamustine Sales Value by Type
    • 3.2.1 Global Bendamustine Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Bendamustine Sales Value, by Type (2020-2031)
    • 3.2.3 Global Bendamustine Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Bendamustine Sales Volume by Type
    • 3.3.1 Global Bendamustine Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Bendamustine Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Bendamustine Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Bendamustine Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Chronic Lymphocytic Leukemia
    • 4.1.2 Multiple Myeloma
    • 4.1.3 Non-Hodgkin's Lymphoma
  • 4.2 Global Bendamustine Sales Value by Application
    • 4.2.1 Global Bendamustine Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Bendamustine Sales Value, by Application (2020-2031)
    • 4.2.3 Global Bendamustine Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Bendamustine Sales Volume by Application
    • 4.3.1 Global Bendamustine Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Bendamustine Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Bendamustine Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Bendamustine Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Bendamustine Sales Value by Region
    • 5.1.1 Global Bendamustine Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Bendamustine Sales Value by Region (2020-2025)
    • 5.1.3 Global Bendamustine Sales Value by Region (2026-2031)
    • 5.1.4 Global Bendamustine Sales Value by Region (%), (2020-2031)
  • 5.2 Global Bendamustine Sales Volume by Region
    • 5.2.1 Global Bendamustine Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Bendamustine Sales Volume by Region (2020-2025)
    • 5.2.3 Global Bendamustine Sales Volume by Region (2026-2031)
    • 5.2.4 Global Bendamustine Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Bendamustine Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Bendamustine Sales Value, 2020-2031
    • 5.4.2 North America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Bendamustine Sales Value, 2020-2031
    • 5.5.2 Europe Bendamustine Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Bendamustine Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Bendamustine Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Bendamustine Sales Value, 2020-2031
    • 5.7.2 South America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Bendamustine Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Bendamustine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Bendamustine Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Bendamustine Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Bendamustine Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Bendamustine Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Bendamustine Sales Value, 2020-2031
    • 6.3.2 United States Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Bendamustine Sales Value, 2020-2031
    • 6.4.2 Europe Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Bendamustine Sales Value, 2020-2031
    • 6.5.2 China Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Bendamustine Sales Value, 2020-2031
    • 6.6.2 Japan Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Bendamustine Sales Value, 2020-2031
    • 6.7.2 South Korea Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Bendamustine Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Bendamustine Sales Value, 2020-2031
    • 6.9.2 India Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Bendamustine Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Teva
    • 7.1.1 Teva Company Information
    • 7.1.2 Teva Introduction and Business Overview
    • 7.1.3 Teva Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Teva Bendamustine Product Offerings
    • 7.1.5 Teva Recent Development
  • 7.2 Eisai
    • 7.2.1 Eisai Company Information
    • 7.2.2 Eisai Introduction and Business Overview
    • 7.2.3 Eisai Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Eisai Bendamustine Product Offerings
    • 7.2.5 Eisai Recent Development
  • 7.3 Eagle Pharmaceuticals
    • 7.3.1 Eagle Pharmaceuticals Company Information
    • 7.3.2 Eagle Pharmaceuticals Introduction and Business Overview
    • 7.3.3 Eagle Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Eagle Pharmaceuticals Bendamustine Product Offerings
    • 7.3.5 Eagle Pharmaceuticals Recent Development
  • 7.4 MundiPharma
    • 7.4.1 MundiPharma Company Information
    • 7.4.2 MundiPharma Introduction and Business Overview
    • 7.4.3 MundiPharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 MundiPharma Bendamustine Product Offerings
    • 7.4.5 MundiPharma Recent Development
  • 7.5 Viatris
    • 7.5.1 Viatris Company Information
    • 7.5.2 Viatris Introduction and Business Overview
    • 7.5.3 Viatris Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Viatris Bendamustine Product Offerings
    • 7.5.5 Viatris Recent Development
  • 7.6 Apotex
    • 7.6.1 Apotex Company Information
    • 7.6.2 Apotex Introduction and Business Overview
    • 7.6.3 Apotex Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Apotex Bendamustine Product Offerings
    • 7.6.5 Apotex Recent Development
  • 7.7 Emcure
    • 7.7.1 Emcure Company Information
    • 7.7.2 Emcure Introduction and Business Overview
    • 7.7.3 Emcure Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Emcure Bendamustine Product Offerings
    • 7.7.5 Emcure Recent Development
  • 7.8 Miracalus Pharma
    • 7.8.1 Miracalus Pharma Company Information
    • 7.8.2 Miracalus Pharma Introduction and Business Overview
    • 7.8.3 Miracalus Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Miracalus Pharma Bendamustine Product Offerings
    • 7.8.5 Miracalus Pharma Recent Development
  • 7.9 Fresenius
    • 7.9.1 Fresenius Company Information
    • 7.9.2 Fresenius Introduction and Business Overview
    • 7.9.3 Fresenius Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Fresenius Bendamustine Product Offerings
    • 7.9.5 Fresenius Recent Development
  • 7.10 Zhengda Tianqing
    • 7.10.1 Zhengda Tianqing Company Information
    • 7.10.2 Zhengda Tianqing Introduction and Business Overview
    • 7.10.3 Zhengda Tianqing Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Zhengda Tianqing Bendamustine Product Offerings
    • 7.10.5 Zhengda Tianqing Recent Development
  • 7.11 Slayback Pharma
    • 7.11.1 Slayback Pharma Company Information
    • 7.11.2 Slayback Pharma Introduction and Business Overview
    • 7.11.3 Slayback Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Slayback Pharma Bendamustine Product Offerings
    • 7.11.5 Slayback Pharma Recent Development
  • 7.12 SYMBIO SEIYAKU
    • 7.12.1 SYMBIO SEIYAKU Company Information
    • 7.12.2 SYMBIO SEIYAKU Introduction and Business Overview
    • 7.12.3 SYMBIO SEIYAKU Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 SYMBIO SEIYAKU Bendamustine Product Offerings
    • 7.12.5 SYMBIO SEIYAKU Recent Development
  • 7.13 Hikma Pharmaceuticals
    • 7.13.1 Hikma Pharmaceuticals Company Information
    • 7.13.2 Hikma Pharmaceuticals Introduction and Business Overview
    • 7.13.3 Hikma Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Hikma Pharmaceuticals Bendamustine Product Offerings
    • 7.13.5 Hikma Pharmaceuticals Recent Development
  • 7.14 Natco Pharma
    • 7.14.1 Natco Pharma Company Information
    • 7.14.2 Natco Pharma Introduction and Business Overview
    • 7.14.3 Natco Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 Natco Pharma Bendamustine Product Offerings
    • 7.14.5 Natco Pharma Recent Development
  • 7.15 Medac GmbH
    • 7.15.1 Medac GmbH Company Information
    • 7.15.2 Medac GmbH Introduction and Business Overview
    • 7.15.3 Medac GmbH Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.15.4 Medac GmbH Bendamustine Product Offerings
    • 7.15.5 Medac GmbH Recent Development

8 Industry Chain Analysis

  • 8.1 Bendamustine Industrial Chain
  • 8.2 Bendamustine Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Bendamustine Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Bendamustine Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Bendamustine Market Trends
  • Table 2. Bendamustine Market Drivers & Opportunity
  • Table 3. Bendamustine Market Challenges
  • Table 4. Bendamustine Market Restraints
  • Table 5. Global Bendamustine Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Bendamustine Revenue Market Share by Company (2020-2025)
  • Table 7. Global Bendamustine Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Bendamustine Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Bendamustine Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Bendamustine Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Bendamustine Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Bendamustine
  • Table 13. Global Bendamustine Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bendamustine as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Bendamustine Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Bendamustine Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Bendamustine Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Bendamustine Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Bendamustine Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Bendamustine Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Bendamustine Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Bendamustine Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Bendamustine Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Bendamustine Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Bendamustine Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Bendamustine Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Bendamustine Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Bendamustine Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Bendamustine Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Bendamustine Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Bendamustine Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Bendamustine Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Bendamustine Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Bendamustine Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Bendamustine Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Bendamustine Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Bendamustine Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Bendamustine Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Bendamustine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Bendamustine Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Bendamustine Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Bendamustine Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Bendamustine Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Bendamustine Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Bendamustine Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Bendamustine Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Bendamustine Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Bendamustine Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Bendamustine Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Bendamustine Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Bendamustine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Bendamustine Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Bendamustine Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Bendamustine Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Bendamustine Sales Volume, (2026-2031) & (K Units)
  • Table 57. Teva Company Information
  • Table 58. Teva Introduction and Business Overview
  • Table 59. Teva Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Teva Bendamustine Product Offerings
  • Table 61. Teva Recent Development
  • Table 62. Eisai Company Information
  • Table 63. Eisai Introduction and Business Overview
  • Table 64. Eisai Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Eisai Bendamustine Product Offerings
  • Table 66. Eisai Recent Development
  • Table 67. Eagle Pharmaceuticals Company Information
  • Table 68. Eagle Pharmaceuticals Introduction and Business Overview
  • Table 69. Eagle Pharmaceuticals Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. Eagle Pharmaceuticals Bendamustine Product Offerings
  • Table 71. Eagle Pharmaceuticals Recent Development
  • Table 72. MundiPharma Company Information
  • Table 73. MundiPharma Introduction and Business Overview
  • Table 74. MundiPharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. MundiPharma Bendamustine Product Offerings
  • Table 76. MundiPharma Recent Development
  • Table 77. Viatris Company Information
  • Table 78. Viatris Introduction and Business Overview
  • Table 79. Viatris Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Viatris Bendamustine Product Offerings
  • Table 81. Viatris Recent Development
  • Table 82. Apotex Company Information
  • Table 83. Apotex Introduction and Business Overview
  • Table 84. Apotex Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Apotex Bendamustine Product Offerings
  • Table 86. Apotex Recent Development
  • Table 87. Emcure Company Information
  • Table 88. Emcure Introduction and Business Overview
  • Table 89. Emcure Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Emcure Bendamustine Product Offerings
  • Table 91. Emcure Recent Development
  • Table 92. Miracalus Pharma Company Information
  • Table 93. Miracalus Pharma Introduction and Business Overview
  • Table 94. Miracalus Pharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Miracalus Pharma Bendamustine Product Offerings
  • Table 96. Miracalus Pharma Recent Development
  • Table 97. Fresenius Company Information
  • Table 98. Fresenius Introduction and Business Overview
  • Table 99. Fresenius Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Fresenius Bendamustine Product Offerings
  • Table 101. Fresenius Recent Development
  • Table 102. Zhengda Tianqing Company Information
  • Table 103. Zhengda Tianqing Introduction and Business Overview
  • Table 104. Zhengda Tianqing Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. Zhengda Tianqing Bendamustine Product Offerings
  • Table 106. Zhengda Tianqing Recent Development
  • Table 107. Slayback Pharma Company Information
  • Table 108. Slayback Pharma Introduction and Business Overview
  • Table 109. Slayback Pharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 110. Slayback Pharma Bendamustine Product Offerings
  • Table 111. Slayback Pharma Recent Development
  • Table 112. SYMBIO SEIYAKU Company Information
  • Table 113. SYMBIO SEIYAKU Introduction and Business Overview
  • Table 114. SYMBIO SEIYAKU Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 115. SYMBIO SEIYAKU Bendamustine Product Offerings
  • Table 116. SYMBIO SEIYAKU Recent Development
  • Table 117. Hikma Pharmaceuticals Company Information
  • Table 118. Hikma Pharmaceuticals Introduction and Business Overview
  • Table 119. Hikma Pharmaceuticals Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 120. Hikma Pharmaceuticals Bendamustine Product Offerings
  • Table 121. Hikma Pharmaceuticals Recent Development
  • Table 122. Natco Pharma Company Information
  • Table 123. Natco Pharma Introduction and Business Overview
  • Table 124. Natco Pharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 125. Natco Pharma Bendamustine Product Offerings
  • Table 126. Natco Pharma Recent Development
  • Table 127. Medac GmbH Company Information
  • Table 128. Medac GmbH Introduction and Business Overview
  • Table 129. Medac GmbH Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 130. Medac GmbH Bendamustine Product Offerings
  • Table 131. Medac GmbH Recent Development
  • Table 132. Key Raw Materials Lists
  • Table 133. Raw Materials Key Suppliers Lists
  • Table 134. Bendamustine Downstream Customers
  • Table 135. Bendamustine Distributors List
  • Table 136. Research Programs/Design for This Report
  • Table 137. Key Data Information from Secondary Sources
  • Table 138. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Bendamustine Product Picture
  • Figure 2. Global Bendamustine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Bendamustine Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Bendamustine Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Bendamustine Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Bendamustine Report Years Considered
  • Figure 7. Global Bendamustine Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Bendamustine Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Bendamustine Revenue in 2024
  • Figure 10. Bendamustine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. 25mg Injection Picture
  • Figure 12. 100mg Injection Picture
  • Figure 13. Others Picture
  • Figure 14. Global Bendamustine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Bendamustine Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Bendamustine Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 17. Global Bendamustine Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Bendamustine Price by Type (2020-2031) & (USD/Unit)
  • Figure 19. Product Picture of Chronic Lymphocytic Leukemia
  • Figure 20. Product Picture of Multiple Myeloma
  • Figure 21. Product Picture of Non-Hodgkin's Lymphoma
  • Figure 22. Global Bendamustine Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global Bendamustine Sales Value Market Share by Application, 2024 & 2031
  • Figure 24. Global Bendamustine Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 25. Global Bendamustine Sales Volume Market Share by Application, 2024 & 2031
  • Figure 26. Global Bendamustine Price by Application (2020-2031) & (USD/Unit)
  • Figure 27. North America Bendamustine Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific Bendamustine Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions Bendamustine Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions Bendamustine Sales Volume (%), (2020-2031)
  • Figure 39. United States Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Europe Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 45. China Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Japan Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 51. South Korea Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Southeast Asia Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 57. India Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 60. Bendamustine Industrial Chain
  • Figure 61. Bendamustine Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed